Oncology Drugs MGR 2017

Oncology Drugs MGR 2017


  • Products Id :- TBRC2101
  • |
  • Pages: 125
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Oncology Drugs market covers drugs that are used in the treatment of a wide range of cancer, sarcoma, and tumor. Some of the bestselling oncology drugs in 2016 include Avastin, Herceptin, Revlimid, MabThera/Rituxan, Gleevac/Glivec, Alimta, Zytiga, Tasigna, Sandostatin, and Afinitor.

The global oncology drugs market was estimated to be around $118 billion as of 2016. The oncology drugs market market made up around 11% of the overall pharmaceuticals market in 2016. The oncology drugs market was the fifth largest market in the global pharmaceutical market in 2016.

R&D Activities

Increase in usage of biotechnological technologies in the development of anticancer drugs such as immunotherapies or monoclonal antibodies, adoptive-cell therapies, and new vaccines is an emerging trend in this market. Major competitors such as Roche, Eli Lilly, Genentech, Pfizer, and Biogen Idec are focusing on the R&D of new technologies such as next generation sequencing to develop MABs that are used for the development of chronic diseases such as cancer and other chronic diseases.

The Oncology Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global oncology drugs sector.

Reasons to Purchase

Outperform competitors using accurate up to date demand-side dynamics information.

Identify growth segments for investment.

Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.

Create regional and country strategies on the basis of local data and analysis.

Stay abreast of the latest customer and market research findings

Benchmark performance against key competitors.

Develop strategies based on likely future developments.

Utilize the relationships between key data sets for superior strategizing.

Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Gain a global perspective on the development of the market.

Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:

Where is the largest and fastest growing market for the oncology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.

The market characteristics section of the report defines and explains the market.

The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down market into sub markets.

The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.

The oncology drugs market section of the report gives context. It compares the oncology drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Oncology Drugs Indicators Comparison.

The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.

Scope

Markets Covered: Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer , Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood Cancer, Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)

Companies Mentioned: F. Hoffmann-La Roche Ltd, Novartis AG, Celgene, Johnson & Johnson, and Bristol-Myers Squibb Company

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Oncology Drugs Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1. Oncology Drugs Market Characteristics;

2. Oncology Drugs Market Size And Growth;

2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;

3. Pestle Analysis;

3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;

4. Oncology Drugs Market Customer Information;

5. Oncology Drugs Market Segmentation;

5.1. Global Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 5.2. Global Oncology Drugs Market, 2012-2020, Historic And Forecast, By Segment; 5.3 Global Oncology Drugs Market Trends And Strategies;

6. Oncology Drugs Market Regional And Country Analysis;

6.1. Global Oncology Drugs Market, 2016, By Region; 6.2. Global Oncology Drugs Market, 2012-2020, Historic And Forecast, By Region; 6.3. Oncology Drugs Market, 2016, By Country; 6.4. Oncology Drugs Market, 2012-2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country

7. Global Oncology Drugs Market Comparison With Macro Economic Factors;

7.1. Oncology Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Oncology Drugs Expenditure, Global;

8. Oncology Drugs Market Comparison With Macro Economic Factors Across Countries;

8.1. Oncology Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Oncology Drugs Expenditure, By Country;

9. Oncology Drugs Market Comparison With Industry Metrics;

9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Oncology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Oncology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Oncology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Oncology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Cancer, 2016, By Country;

10. Asia-Pacific Oncology Drugs Market;

10.1.1. Asia-Pacific Oncology Drugs Market Overview; 10.1.2. Asia-Pacific Oncology Drugs Historic Market, 2012-2016; 10.1.3. Asia-Pacific Oncology Drugs Forecast Market, 2016-2020; 10.1.4. Asia-Pacific Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.2. Asia-Pacific Oncology Drugs Market: Country Analysis; 10.3. China Oncology Drugs Market; 10.3.1. China Oncology Drugs Market Overview; 10.3.2. China Oncology Drugs Historic Market, 2012-2016; 10.3.3. China Oncology Drugs Forecast Market, 2016-2020; 10.3.4. China Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.3.5. China Oncology Drugs Percentage Of GDP, 2012-2020; 10.3.6. China Per Capita Average Oncology Drugs Expenditure, 2012-2020; 10.4. India Oncology Drugs Market; 10.4.1. India Oncology Drugs Market Overview; 10.4.2. India Oncology Drugs Historic Market, 2012-2016; 10.4.3. India Oncology Drugs Forecast Market, 2016-2020; 10.4.4. India Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.4.5. India Oncology Drugs Percentage Of GDP, 2012-2020; 10.4.6. India Per Capita Average Oncology Drugs Expenditure, 2012-2020; 10.5. Japan Oncology Drugs Market; 10.5.1. Japan Oncology Drugs Market Overview; 10.5.2. Japan Oncology Drugs Historic Market, 2012-2016; 10.5.3. Japan Oncology Drugs Forecast Market, 2016-2020; 10.5.4. Japan Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.5.5. Japan Oncology Drugs Percentage Of GDP, 2012-2020; 10.5.6. Japan Per Capita Average Oncology Drugs Expenditure, 2012-2020; 10.6. Australia Oncology Drugs Market; 10.6.1. Australia Oncology Drugs Historic Market, 2012-2016; 10.6.2. Australia Oncology Drugs Forecast Market, 2016-2020; 10.6.3. Australia Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.6.4. Australia Oncology Drugs Percentage Of GDP, 2012-2020; 10.6.5. Australia Per Capita Average Oncology Drugs Expenditure, 2012-2020;

11. Western Europe Oncology Drugs Market;

11.1.1. Western Europe Oncology Drugs Market Overview; 11.1.2. Western Europe Oncology Drugs Historic Market, 2012-2016; 11.1.3. Western Europe Oncology Drugs Forecast Market, 2016-2020; 11.1.4. Western Europe Oncology Drugs Market, 2016, By Segment; Lung Cancer; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.2. Western Europe Oncology Drugs Market: Country Analysis; 11.3. UK Oncology Drugs Market; 11.3.1. UK Oncology Drugs Market Overview; 11.3.2. UK Oncology Drugs Historic Market, 2012-2016; 11.3.3. UK Oncology Drugs Forecast Market, 2016-2020; 11.3.4. UK Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.3.5. UK Oncology Drugs Percentage Of GDP, 2012-2020; 11.3.6. UK Per Capita Average Oncology Drugs Expenditure, 2012-2020; 11.4. Germany Oncology Drugs Market; 11.4.1. Germany Oncology Drugs Historic Market, 2012-2016; 11.4.2. Germany Oncology Drugs Forecast Market, 2016-2020; 11.4.3. Germany Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.4.4 Germany Oncology Drugs Percentage Of GDP, 2012-2020; 11.4.5 Germany Per Capita Average Oncology Drugs Expenditure, 2012-2020; 11.5 France Oncology Drugs Market; 11.5.1 France Oncology Drugs Historic Market, 2012-2016; 11.5.2 France Oncology Drugs Forecast Market, 2016-2020; 11.5.3 France Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.5.4 France Oncology Drugs Percentage Of GDP, 2012-2020; 11.5.5 France Per Capita Average Oncology Drugs Expenditure, 2012-2020; 11.6. Italy Oncology Drugs Market; 11.6.2. Italy Oncology Drugs Forecast Market, 2016-2020; 11.6.3. Italy Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.6.4. Italy Oncology Drugs Percentage Of GDP, 2012-2020; 11.6.5. Italy Per Capita Average Oncology Drugs Expenditure, 2012-2020; 11.7. Spain Oncology Drugs Market; 11.7.1. Spain Oncology Drugs Historic Market, 2012-2016; 11.7.2. Spain Oncology Drugs Forecast Market, 2016-2020; 11.7.3. Spain Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.7.4. Spain Oncology Drugs Percentage Of GDP, 2012-2020; 11.7.5. Spain Per Capita Average Oncology Drugs Expenditure, 2012-2020;

12. Eastern Europe Oncology Drugs Market;

12.1.1. Eastern Europe Oncology Drugs Market Overview; 12.1.2. Eastern Europe Oncology Drugs Historic Market, 2012-2016; 12.1.3. Eastern Europe Oncology Drugs Forecast Market, 2016-2020; 12.1.4 Eastern Europe Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 12.2. Eastern Europe Oncology Drugs Market: Country Analysis; 12.3. Russia Oncology Drugs Market; 12.3.1. Russia Oncology Drugs Historic Market, 2012-2016; 12.3.2. Russia Oncology Drugs Forecast Market, 2016-2020; 12.3.3. Russia Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 12.3.4. Russia Oncology Drugs Percentage Of GDP, 2012-2020; 12.3.5. Russia Per Capita Average Oncology Drugs Expenditure, 2012-2020;

13. North America Oncology Drugs Market;

13.1.1. North America Oncology Drugs Market Overview; 13.1.2. North America Oncology Drugs Historic Market, 2012-2016; 13.1.3. North America Oncology Drugs Forecast Market, 2016-2020; 13.1.4. North America Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 13.2. North America Oncology Drugs Market: Country Analysis; 13.3. USA Oncology Drugs Market; 13.3.1. USA Oncology Drugs Historic Market, 2012-2016; 13.3.2. USA Oncology Drugs Forecast Market, 2016-2020; 13.3.3 USA Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 13.3.4. USA Oncology Drugs Percentage Of GDP, 2012-2020; 13.3.5. USA Per Capita Average Oncology Drugs Expenditure, 2012-2020;

14. South America Oncology Drugs Market;

14.1.1. South America Oncology Drugs Market Overview; 14.1.2. South America Oncology Drugs Historic Market, 2012-2016; 14.1.3. South America Oncology Drugs Forecast Market, 2016-2020; 14.1.4. South America Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 14.2. South America Oncology Drugs Market: Country Analysis; 14.3. Brazil Oncology Drugs Market; 14.3.1. Brazil Oncology Drugs Historic Market, 2012-2016; 14.3.2. Brazil Oncology Drugs Forecast Market, 2016-2020; 14.3.3. Brazil Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 14.3.4. Brazil Oncology Drugs Percentage Of GDP, 2012-2020; 14.3.5. Brazil Per Capita Average Oncology Drugs Expenditure, 2012-2020;

15. Middle East Oncology Drugs Market;

15.1.1. Middle East Oncology Drugs Market Overview; 15.1.2. Middle East Oncology Drugs Historic Market, 2012-2016; 15.1.3. Middle East Oncology Drugs Forecast Market, 2016-2020; 15.1.4. Middle East Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma);

16. Africa Oncology Drugs Market;

16.1.1. Africa Oncology Drugs Market Overview; 16.1.2. Africa Oncology Drugs Historic Market, 2012-2016; 16.1.3. Africa Oncology Drugs Forecast Market, 2016-2020; 16.1.4. Africa Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma);

17. Oncology Drugs Market Competitive Landscape;

17.1. Company Profiles; 17.2. F. Hoffmann-La Roche Ltd; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Novartis Ag; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Celgene; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Johnson & Johnson; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Bristol-Myers Squibb Company 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;

18. Key Mergers And Acquisitions In The Oncology Drugs Market;

19. Market Background: Pharmaceutical Drugs Market;

19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;

20. Pharmaceuticals Industry Financial Margins;

21. Appendix;

21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer

Table 1: Global Oncology Drugs Historic Market Growth

Table 2: Global Oncology Drugs Forecast Market Growth

Table 3: Oncology Drugs Market Segmentation

Table 4: Global Oncology Drugs Market, 2016, By Segment

Table 5: Global Oncology Drugs Market, 2012-2020, Historic And Forecast, By Segment

Table 6: Global Oncology Drugs Market, 2016, By Region

Table 7: Global Oncology Drugs Market, 2012-2020, Historic And Forecast, By Region

Table 8: Oncology Drugs Market, 2016, By Country

Table 9: Oncology Drugs Market, 2012-2020, Historic And Forecast, By Country

Table 10: Oncology Drugs Market Size, Percentage Of GDP, Global

Table 11: Per Capita Average Oncology Drugs Expenditure, Global

Table 12: Oncology Drugs Market Comparison With Macro Economic Factors Across Countries

Table 13: Oncology Drugs Market Size, Percentage Of GDP, By Country

Table 14: Per Capita Average Oncology Drugs Expenditure, By Country

Table 15: Global Number Of Pharmacists, 2016, By Country

Table 16: Global Oncology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country

Table 17: Global Number Of Pharma Enterprises, 2016, By Country

Table 18: Global Oncology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Table 19: Global Average Spending On R&D/Product Development, 2016, By Country

Table 20: Global Oncology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Table 21: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 22: Global Oncology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 23: Prevalent Cases Of Cancer, 2016, By Country

Table 24: Asia-Pacific Oncology Drugs Historic Market, 2012-2016

Table 25: Asia-Pacific Oncology Drugs Forecast Market, 2016-2020

Table 26: Asia-Pacific Oncology Drugs Market, 2016, By Segment

Table 27: China Oncology Drugs Historic Market, 2012-2016

Table 28: China Oncology Drugs Forecast Market, 2016-2020

Table 29: China Oncology Drugs Market, 2016, By Segment

Table 30: China Oncology Drugs Percentage Of GDP, 2012-2020

Table 31: China Per Capita Average Oncology Drugs Expenditure, 2012-2020

Table 32: India Oncology Drugs Historic Market, 2012-2016

Table 33: India Oncology Drugs Forecast Market, 2016-2020

Table 34: India Oncology Drugs Market, 2016, By Segment

Table 35: India Oncology Drugs Percentage Of GDP, 2012-2020

Table 36: India Per Capita Average Oncology Drugs Expenditure, 2012-2020

Table 37: Japan Oncology Drugs Historic Market, 2012-2016

Table 38: Japan Oncology Drugs Forecast Market, 2016-2020

Table 39: Japan Oncology Drugs Market, 2016, By Segment

Table 40: Japan Oncology Drugs Percentage Of GDP, 2012-2020

Table 41: Japan Per Capita Average Oncology Drugs Expenditure, 2012-2020

Table 42: Australia Oncology Drugs Historic Market, 2012-2016

Table 43: Australia Oncology Drugs Forecast Market, 2016-2020

Table 44: Australia Oncology Drugs Market, 2016, By Segment

Table 45: Australia Oncology Drugs Percentage Of GDP, 2012-2020

Table 46: Australia Per Capita Average Oncology Drugs Expenditure, 2012-2020

Table 47: Western Europe Oncology Drugs Historic Market, 2012-2016

Table 48: Western Europe Oncology Drugs Forecast Market, 2016-2020

Table 49: Western Europe Oncology Drugs Market, 2016, By Segment

Table 50: UK Oncology Drugs Historic Market, 2012-2016

Table 51: UK Oncology Drugs Forecast Market, 2016-2020

Table 52: UK Oncology Drugs Market, 2016, By Segment

Table 53: UK Oncology Drugs Percentage Of GDP, 2012-2020

Table 54: UK Per Capita Average Oncology Drugs Expenditure, 2012-2020

Table 55: Germany Oncology Drugs Historic Market, 2012-2016

Table 56: Germany Oncology Drugs Forecast Market, 2016-2020

Table 57: Germany Oncology Drugs Market, 2016, By Segment

Table 58: Germany Oncology Drugs Percentage Of GDP, 2012-2020

Table 59: Germany Per Capita Average Oncology Drugs Expenditure, 2012-2020

Table 60: France Oncology Drugs Historic Market, 2012-2016

Table 61: France Oncology Drugs Forecast Market, 2016-2020

Table 62: France Oncology Drugs Market, 2016, By Segment

Table 63: France Oncology Drugs Percentage Of GDP, 2012-2020

Table 64: France Per Capita Average Oncology Drugs Expenditure, 2012-2020

Table 65: Italy Oncology Drugs Historic Market, 2012-2016

Table 66: Italy Oncology Drugs Forecast Market, 2016-2020

Table 67: Italy Oncology Drugs Market, 2016, By Segment

Table 68: Italy Oncology Drugs Percentage Of GDP, 2012-2020

Table 69: Italy Per Capita Average Oncology Drugs Expenditure, 2012-2020

Table 70: Spain Oncology Drugs Historic Market, 2012-2016

Table 71: Spain Oncology Drugs Forecast Market, 2016-2020

Table 72: Spain Oncology Drugs Market, 2016, By Segment

Table 73: Spain Oncology Drugs Percentage Of GDP, 2012-2020

Table 74: Spain Per Capita Average Oncology Drugs Expenditure, 2012-2020

Table 75: Eastern Europe Oncology Drugs Historic Market, 2012-2016

Table 76: Eastern Europe Oncology Drugs Forecast Market, 2016-2020

Table 77: Eastern Europe Oncology Drugs Market, 2016, By Segment

Table 78: Russia Oncology Drugs Historic Market, 2012-2016

Table 79: Russia Oncology Drugs Forecast Market, 2016-2020

Table 80: Russia Oncology Drugs Market, 2016, By Segment

Table 81: Russia Oncology Drugs Percentage Of GDP, 2012-2020

Table 82: Russia Per Capita Average Oncology Drugs Expenditure, 2012-2020

Table 83: North America Oncology Drugs Historic Market, 2012-2016

Table 84: North America Oncology Drugs Forecast Market, 2016-2020

Table 85: North America Oncology Drugs Market, 2016, By Segment

Table 86: USA Oncology Drugs Historic Market, 2012-2016

Table 87: USA Oncology Drugs Forecast Market, 2016-2020

Table 88: USA Oncology Drugs Market, 2016, By Segment

Table 89: USA Oncology Drugs Percentage Of GDP, 2012-2020

Table 90: USA Per Capita Average Oncology Drugs Expenditure, 2012-2020

Table 91: South America Oncology Drugs Historic Market, 2012-2016

Table 92: South America Oncology Drugs Forecast Market, 2016-2020

Table 93: South America Oncology Drugs Market, 2016, By Segment

Table 94: Brazil Oncology Drugs Historic Market, 2012-2016

Table 95: Brazil Oncology Drugs Forecast Market, 2016-2020

Table 96: Brazil Oncology Drugs Market, 2016, By Segment

Table 97: Brazil Oncology Drugs Percentage Of GDP, 2012-2020

Table 98: Brazil Per Capita Average Oncology Drugs Expenditure, 2012-2020

Table 99: Middle East Oncology Drugs Historic Market, 2012-2016

Table 100: Middle East Oncology Drugs Forecast Market, 2016-2020

Table 101: Middle East Oncology Drugs Market, 2016, By Segment

Table 102: Africa Oncology Drugs Historic Market, 2012-2016

Table 103: Africa Oncology Drugs Forecast Market, 2016-2020

Table 104: Africa Oncology Drugs Market, 2016, By Segment

Table 105: F. Hoffmann-La Roche Ltd Financial Performance

Table 106: Novartis Ag Financial Performance

Table 107: Celgene Financial Performance

Table 108: Johnson & Johnson Financial Performance

Table 109: Bristol-Myers Squibb Company Financial Performance

Table 110: Pharmaceutical Drugs Market Historic Growth

Table 111: Pharmaceutical Drugs Market Forecast Growth

Table 112: Global Pharmaceutical Drugs Market, 2016, By Region

Table 113: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region

Table 114: Pharmaceutical Drugs Market, 2016, By Country

Table 115: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country

Table 116: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment

Table 117: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment

Table 118: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global

Table 119: Per Capita Average Pharmaceutical Drugs Expenditure, Global

Table 120: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries

Table 121: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country

Table 122: Per Capita Average Pharmaceutical Drugs Expenditure, By Country

Table 123: Pharmaceuticals Industry Financial Margins

Figure 1: Global Oncology Drugs Historic Market Growth

Figure 2: Global Oncology Drugs Forecast Market Growth

Figure 3: Oncology Drugs Market Segmentation

Figure 4: Global Oncology Drugs Market, 2016, By Segment

Figure 5: Global Oncology Drugs Market, 2012-2020, Historic And Forecast, By Segment

Figure 6: Global Oncology Drugs Market, 2016, By Region

Figure 7: Global Oncology Drugs Market, 2012-2020, Historic And Forecast, By Region

Figure 8: Oncology Drugs Market, 2016, By Country

Figure 9: Oncology Drugs Market, 2012-2020, Historic And Forecast, By Country

Figure 10: Oncology Drugs Market Size, Percentage Of GDP, Global

Figure 11: Per Capita Average Oncology Drugs Expenditure, Global

Figure 12: Oncology Drugs Market Comparison With Macro Economic Factors Across Countries

Figure 13: Oncology Drugs Market Size, Percentage Of GDP, By Country

Figure 14: Per Capita Average Oncology Drugs Expenditure, By Country

Figure 15: Global Number Of Pharmacists, 2016, By Country

Figure 16: Global Oncology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country

Figure 17: Global Number Of Pharma Enterprises, 2016, By Country

Figure 18: Global Oncology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Figure 19: Global Average Spending On R&D/Product Development, 2016, By Country

Figure 20: Global Oncology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Figure 21: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 22: Global Oncology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 23: Prevalent Cases Of Cancer, 2016, By Country

Figure 24: Asia-Pacific Oncology Drugs Historic Market, 2012-2016

Figure 25: Asia-Pacific Oncology Drugs Forecast Market, 2016-2020

Figure 26: Asia-Pacific Oncology Drugs Market, 2016, By Segment

Figure 27: China Oncology Drugs Historic Market, 2012-2016

Figure 28: China Oncology Drugs Forecast Market, 2016-2020

Figure 29: China Oncology Drugs Market, 2016, By Segment

Figure 30: China Oncology Drugs Percentage Of GDP, 2012-2020

Figure 31: China Per Capita Average Oncology Drugs Expenditure, 2012-2020

Figure 32: India Oncology Drugs Historic Market, 2012-2016

Figure 33: India Oncology Drugs Forecast Market, 2016-2020

Figure 34: India Oncology Drugs Market, 2016, By Segment

Figure 35: India Oncology Drugs Percentage Of GDP, 2012-2020

Figure 36: India Per Capita Average Oncology Drugs Expenditure, 2012-2020

Figure 37: Japan Oncology Drugs Historic Market, 2012-2016

Figure 38: Japan Oncology Drugs Forecast Market, 2016-2020

Figure 39: Japan Oncology Drugs Market, 2016, By Segment

Figure 40: Japan Oncology Drugs Percentage Of GDP, 2012-2020

Figure 41: Japan Per Capita Average Oncology Drugs Expenditure, 2012-2020

Figure 42: Australia Oncology Drugs Historic Market, 2012-2016

Figure 43: Australia Oncology Drugs Forecast Market, 2016-2020

Figure 44: Australia Oncology Drugs Market, 2016, By Segment

Figure 45: Australia Oncology Drugs Percentage Of GDP, 2012-2020

Figure 46: Australia Per Capita Average Oncology Drugs Expenditure, 2012-2020

Figure 47: Western Europe Oncology Drugs Historic Market, 2012-2016

Figure 48: Western Europe Oncology Drugs Forecast Market, 2016-2020

Figure 49: Western Europe Oncology Drugs Market, 2016, By Segment

Figure 50: UK Oncology Drugs Historic Market, 2012-2016

Figure 51: UK Oncology Drugs Forecast Market, 2016-2020

Figure 52: UK Oncology Drugs Market, 2016, By Segment

Figure 53: UK Oncology Drugs Percentage Of GDP, 2012-2020

Figure 54: UK Per Capita Average Oncology Drugs Expenditure, 2012-2020

Figure 55: Germany Oncology Drugs Historic Market, 2012-2016

Figure 56: Germany Oncology Drugs Forecast Market, 2016-2020

Figure 57: Germany Oncology Drugs Market, 2016, By Segment

Figure 58: Germany Oncology Drugs Percentage Of GDP, 2012-2020

Figure 59: Germany Per Capita Average Oncology Drugs Expenditure, 2012-2020

Figure 60: France Oncology Drugs Historic Market, 2012-2016

Figure 61: France Oncology Drugs Forecast Market, 2016-2020

Figure 62: France Oncology Drugs Market, 2016, By Segment

Figure 63: France Oncology Drugs Percentage Of GDP, 2012-2020

Figure 64: France Per Capita Average Oncology Drugs Expenditure, 2012-2020

Figure 65: Italy Oncology Drugs Historic Market, 2012-2016

Figure 66: Italy Oncology Drugs Forecast Market, 2016-2020

Figure 67: Italy Oncology Drugs Market, 2016, By Segment

Figure 68: Italy Oncology Drugs Percentage Of GDP, 2012-2020

Figure 69: Italy Per Capita Average Oncology Drugs Expenditure, 2012-2020

Figure 70: Spain Oncology Drugs Historic Market, 2012-2016

Figure 71: Spain Oncology Drugs Forecast Market, 2016-2020

Figure 72: Spain Oncology Drugs Market, 2016, By Segment

Figure 73: Spain Oncology Drugs Percentage Of GDP, 2012-2020

Figure 74: Spain Per Capita Average Oncology Drugs Expenditure, 2012-2020

Figure 75: Eastern Europe Oncology Drugs Historic Market, 2012-2016

Figure 76: Eastern Europe Oncology Drugs Forecast Market, 2016-2020

Figure 77: Eastern Europe Oncology Drugs Market, 2016, By Segment

Figure 78: Russia Oncology Drugs Historic Market, 2012-2016

Figure 79: Russia Oncology Drugs Forecast Market, 2016-2020

Figure 80: Russia Oncology Drugs Market, 2016, By Segment

Figure 81: Russia Oncology Drugs Percentage Of GDP, 2012-2020

Figure 82: Russia Per Capita Average Oncology Drugs Expenditure, 2012-2020

Figure 83: North America Oncology Drugs Historic Market, 2012-2016

Figure 84: North America Oncology Drugs Forecast Market, 2016-2020

Figure 85: North America Oncology Drugs Market, 2016, By Segment

Figure 86: USA Oncology Drugs Historic Market, 2012-2016

Figure 87: USA Oncology Drugs Forecast Market, 2016-2020

Figure 88: USA Oncology Drugs Market, 2016, By Segment

Figure 89: USA Oncology Drugs Percentage Of GDP, 2012-2020

Figure 90: USA Per Capita Average Oncology Drugs Expenditure, 2012-2020

Figure 91: South America Oncology Drugs Historic Market, 2012-2016

Figure 92: South America Oncology Drugs Forecast Market, 2016-2020

Figure 93: South America Oncology Drugs Market, 2016, By Segment

Figure 94: Brazil Oncology Drugs Historic Market, 2012-2016

Figure 95: Brazil Oncology Drugs Forecast Market, 2016-2020

Figure 96: Brazil Oncology Drugs Market, 2016, By Segment

Figure 97: Brazil Oncology Drugs Percentage Of GDP, 2012-2020

Figure 98: Brazil Per Capita Average Oncology Drugs Expenditure, 2012-2020

Figure 99: Middle East Oncology Drugs Historic Market, 2012-2016

Figure 100: Middle East Oncology Drugs Forecast Market, 2016-2020

Figure 101: Middle East Oncology Drugs Market, 2016, By Segment

Figure 102: Africa Oncology Drugs Historic Market, 2012-2016

Figure 103: Africa Oncology Drugs Forecast Market, 2016-2020

Figure 104: Africa Oncology Drugs Market, 2016, By Segment

Figure 105: F. Hoffmann-La Roche Ltd Financial Performance

Figure 106: Novartis Ag Financial Performance

Figure 107: Celgene Financial Performance

Figure 108: Johnson & Johnson Financial Performance

Figure 109: Bristol-Myers Squibb Company Financial Performance

Figure 110: Pharmaceutical Drugs Market Historic Growth

Figure 111: Pharmaceutical Drugs Market Forecast Growth

Figure 112: Global Pharmaceutical Drugs Market, 2016, By Region

Figure 113: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region

Figure 114: Pharmaceutical Drugs Market, 2016, By Country

Figure 115: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country

Figure 116: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment

Figure 117: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment

Figure 118: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global

Figure 119: Per Capita Average Pharmaceutical Drugs Expenditure, Global

Figure 120: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries

Figure 121: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country

Figure 122: Per Capita Average Pharmaceutical Drugs Expenditure, By Country

Figure 123: Pharmaceuticals Industry Financial Margins

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

F. Hoffmann-La Roche Ltd, Novartis AG, Celgene, Johnson & Johnson, and Bristol-Myers Squibb Company

Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer , Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood Cancer, Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)

select a license

Single User License
USD 4000 INR 257920
Hard Copy License
USD 4000 INR 257920
CD-Rom
USD 4000 INR 257920
Site License
USD 6000 INR 386880
Corporate User License
USD 8000 INR 515840

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com